IgG与IgM对脂多糖诱导免疫抑制的保护作用
本研究在本地繁育的BALB/c小鼠中建立脂多糖内毒素血症模型,采用每日腹腔注射0.2 μg/g脂多糖、连续5天的方案,该方案半数动物可耐受。脂多糖处理显著降低CD4+、CD8+、CD3z+和CD19+细胞,同时增加髓源性抑制细胞(MDSCs;CD11b+Gr1+)、CD25+和Foxp3+细胞,并伴脾细胞裂解物精氨酸酶-1活性升高及血清IL-6、TNF-α、IL-18和C反应蛋白升高;血清降钙素原水平未改变。脂多糖处理的脾脏MDSCs在共培养中抑制初始T细胞增殖。体外加入IgG和IgM可显著减少共培养中的CD25+、Foxp3+和CD3z+细胞;体内应用IgG和IgM显著降低脾脏CD11b+Gr1+、CD25+、Foxp3+细胞比例及精氨酸酶-1活性,降低血清IL-6、TNF-α和CRP水平,并使全部受试动物存活。
要点
- 脂多糖方案为每日腹腔注射0.2 μg/g、连续5天,该方案半数受试动物可耐受,可实现较长生存。
- 脂多糖处理显著降低CD4+、CD8+、CD3z+、CD19+细胞,升高MDSCs(CD11b+Gr1+)、CD25+、Foxp3+细胞及脾脏精氨酸酶-1活性。
- 脂多糖处理升高血清IL-6、TNF-α、IL-18和CRP,未改变血清降钙素原水平。
- 体外IgG与IgM可显著减少初始T细胞/LPS-MDSCs共培养中的CD25+、Foxp3+、CD3z+细胞,提示抗免疫抑制效应。
- 体内应用IgG与IgM显著降低脾脏CD11b+Gr1+、CD25+、Foxp3+细胞比例及精氨酸酶-1活性,降低血清IL-6、TNF-α和CRP,使全部受试动物存活。
适用人群与场景
- 本地繁育的BALB/c小鼠脂多糖内毒素血症模型;每日腹腔注射0.2 μg/g脂多糖、连续5天,该方案半数受试动物可耐受。
处置流程与药物剂量
- 脂多糖造模方案:每日腹腔注射0.2 μg/g脂多糖,连续5天。
- 体外实验:将IgG和IgM加入初始T细胞/LPS-MDSCs共培养体系。
- 体内实验:对脂多糖处理动物应用IgG和IgM。
研究设计与关键结果
- 研究类型为动物实验;采用每日腹腔注射0.2 μg/g脂多糖、连续5天的方案,该方案半数受试动物可耐受。
- 脂多糖处理显著降低CD4+、CD8+、CD3z+、CD19+细胞,同时增加MDSCs(CD11b+Gr1+)、CD25+和Foxp3+细胞。
- 脂多糖处理伴脾细胞裂解物精氨酸酶-1活性升高及血清IL-6、TNF-α、IL-18和CRP升高,血清降钙素原水平未改变。
- 脂多糖处理的脾脏MDSCs在共培养中降低初始T细胞增殖。
- 体外加入IgG和IgM显著减少共培养中的CD25+、Foxp3+和CD3z+细胞。
- 体内应用IgG和IgM显著降低脾脏CD11b+Gr1+、CD25+、Foxp3+细胞比例及精氨酸酶-1活性,降低血清IL-6、TNF-α和CRP水平,使全部受试动物存活。
证据类型、等级与局限
- 证据类型:动物实验(小鼠脂多糖内毒素血症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果揭示了IgG/IgM在脂多糖内毒素血症中的新作用方式,从而加强了在脓毒症患者中使用免疫球蛋白治疗的做法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Lipopolysaccharide (LPS) is commonly used in murine sepsis models, which are largely associated with immunosuppression and collapse of the immune system. After adapting the LPS treatment to the needs of locally bred BALB/c mice, the present study explored the potential role of IgG and IgM in reversing LPS endotoxemia. The established protocol consisted of five daily intraperitoneal injections of 0.2 μg/g LPS, which was tolerable by half of the manipulated animals. Such a protocol allowed longer survival, necessary in the prospect of therapeutic treatment application. This treatment significantly decreased CD4+, CD8+, CD3z+, and CD19+ cells, while increasing myeloid-derived suppressor cells (MDSCs; CD11b+Gr1+), CD25+ and Foxp3+ cells. These results were accompanied by increased arginase-1 activity in spleen cell lysates and production of IL-6, TNF-α, IL-18, and C-reactive protein (CRP) in the serum. The applied LPS protocol did not alter serum procalcitonin levels. MDSCs isolated from the spleen of LPS-treated animals (LPS-MDSCs) decreased proliferation of naive T cells in coculture experiments. The application of IgG and IgM to the naive T cell/LPS-MDSCs cocultures significantly decreased CD25+, Foxp3+, and CD3z+ cells, indicating an anti-suppressive effect of immunoglobulins. The in vivo application of IgG and IgM significantly decreased the percent of CD11b+Gr1+, CD25+, Foxp3+ cells, and arginase-1 activity in the spleen of LPS-treated animals, while decreasing IL-6, TNF-α, and CRP levels in the serum, allowing survival to all animals tested. In conclusion, these results reveal a novel mode of action of IgG/IgM in LPS endotoxemia, strengthening thus the use of immunoglobulin treatment is septic patients.
参考来源
- Kyvelidou C, Sotiriou D, Zerva I, et al. Protection Against Lipopolysaccharide-Induced Immunosuppression by IgG and IgM. Shock. 2018. PMID: 28682942. doi:10.1097/SHK.0000000000000937
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。